Innovation And Flexibility Drive Success During The COVID-19 Pandemic

By Paul Magreta, Business Development, CDMO Services, Grifols Recombinant Protein CDMO

Grifols Recombinant Protein CDMO is focused on the same flexibility and problem-solving spirit we use daily to rapidly produce custom proteins to battle the current pandemic.

In these exceptional circumstances, what we do matters more than ever.
At Grifols Recombinant Protein CDMO, we produce recombinant proteins for further manufacture that are used in assays to screen donated blood for viral infections, as well as develop manufacturing processes for novel therapeutics. In 2020, we directed resources toward developing new antigens for SARS-CoV-2 immunoassays. While pursuing this crucial endeavor, we also took comprehensive measures to ensure shipments of products and the provision of services.